Navigation Links
InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
Date:8/20/2008

esses grew and remained profitable, on a continued surge in sales. We have successfully implemented our medical diagnostics and medical disposable products distribution plans and these businesses have generated almost six million dollars in sales during the first half of fiscal 2008, quite an accomplishment even in a slowing national economy. We are currently maintaining momentum in what is usually our slowest quarter, perhaps signifying further developments later this year."

For the first six months of fiscal 2008, InstaCare reported revenues of $5,818,076, a gain of 174% from $2,120,131 recorded during the first six months of fiscal 2007. The Company reported an operating profit of $287,034 during the first six months of fiscal 2008 compared with an operating loss of $430,140 recorded during the first six months of fiscal 2007. The Company reported net income of $59,381 for the first six months of fiscal 2008, compared with a net loss of $553,756 reported for the first six months of fiscal 2007.

Forward-Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information, visit the company's Web Site: http://www.instacare.net.

Company Contact:

InstaCare Corp.

Keith Berman

(805) 446-1973

info@in
'/>"/>

SOURCE InstaCare Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
3. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
4. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
5. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
8. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
9. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
10. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
11. CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... 27, 2015 A paper published today, ... portfolio " in Science Translational Medicine, ... to reduce the risk associated with investing in ... new levels of funding for developing so-called "orphan" ... unique collaboration between scientists at the National Center ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY) is to present ... in patients with metastatic renal cancer at the ASCO ... . The data will be presented by Dr. ... Cancer Center in California in ... identifies Ferritin and IL-8 as two baseline biomarkers that ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... and PRAGUE, Czech Republic, Aug. 21 ... organization, today,announced it has completed the acquisition ... (CRO) headquartered in Prague, Czech,Republic. This move ... and,expands its capacity to provide full service ...
... WOODLANDS, Texas, Aug. 21 ,Lexicon Pharmaceuticals, Inc. ... the structure-activity relationship (SAR) of a class ... compounds,under evaluation by the company as potential ... gastrointestinal disorders. LX1031 is currently,under evaluation in ...
Cached Biology Technology:Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... at Northwestern University Feinberg School of Medicine played ... approval of Abraxane (paclitaxel protein-bound particles for injectable ... cancer. "The approval means that women with metastatic ... toxicities associated with solvents and will no longer ...
... Hopkins Medical Institutions in Baltimore, Md., reports that whole-body ... identify new, unexpected malignant cancerous tumors in patients, according ... Society of Nuclear Medicine's Journal of Nuclear Medicine. , ... to have cancer," said SNM member Richard L. Wahl, ...
... and Drug Administration (FDA) was "the single greatest obstacle ... safety officer David Graham at an unprecedented roundtable of ... (PLoS) and the Government Accountability Project. , In comments ... Senate Finance Committee, Graham said that, "Nearly 60,000 people ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2Medical whistleblowers speak out 2Medical whistleblowers speak out 3
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
... Stem Cell Expansion Kit - Neurosphere is a ... stem cell expansion as neurospheres in a serum ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
Biology Products: